TY - JOUR
T1 - What we learn about bipolar disorder from large-scale neuroimaging: Findings and future directions from the ENIGMA Bipolar Disorder Working Group
T2 - Findings and future directions from the ENIGMA Bipolar Disorder Working Group
AU - Ching, Christopher R. K.
AU - Hibar, Derrek P.
AU - Gurholt, Tiril P.
AU - Nunes, Abraham
AU - Thomopoulos, Sophia I.
AU - Abé, Christoph
AU - Agartz, Ingrid
AU - Brouwer, Rachel M.
AU - Cannon, Dara M.
AU - de Zwarte, Sonja M. C.
AU - Eyler, Lisa T.
AU - Favre, Pauline
AU - Hajek, Tomas
AU - Haukvik, Unn K.
AU - Houenou, Josselin
AU - Landén, Mikael
AU - Lett, Tristram A.
AU - McDonald, Colm
AU - Nabulsi, Leila
AU - Patel, Yash
AU - Pauling, Melissa E.
AU - Paus, Tomas
AU - Radua, Joaquim
AU - Soeiro-de-Souza, Marcio G.
AU - Tronchin, Giulia
AU - van Haren, Neeltje E. M.
AU - Vieta, Eduard
AU - Walter, Henrik
AU - Zeng, Ling-Li
AU - Alda, Martin
AU - Almeida, Jorge
AU - Alnæs, Dag
AU - Alonso-Lana, Silvia
AU - Altimus, Cara
AU - Bauer, Michael
AU - Baune, Bernhard T.
AU - Bearden, Carrie E.
AU - Bellani, Marcella
AU - Benedetti, Francesco
AU - Berk, Michael
AU - Bilderbeck, Amy C.
AU - Blumberg, Hilary P.
AU - Bøen, Erlend
AU - Bollettini, Irene
AU - del Mar Bonnin, Caterina
AU - Brambilla, Paolo
AU - Canales-Rodríguez, Erick J.
AU - Caseras, Xavier
AU - Dandash, Orwa
AU - Dannlowski, Udo
AU - Delvecchio, Giuseppe
AU - Díaz-Zuluaga, Ana M.
AU - Dima, Danai
AU - Duchesnay, Édouard
AU - Elvsåshagen, Torbjørn
AU - Fears, Scott C.
AU - Frangou, Sophia
AU - Fullerton, Janice M.
AU - Glahn, David C.
AU - Goikolea, Jose M.
AU - Green, Melissa J.
AU - Grotegerd, Dominik
AU - Gruber, Oliver
AU - Haarman, Bartholomeus C. M.
AU - Henry, Chantal
AU - Howells, Fleur M.
AU - Ives-Deliperi, Victoria
AU - Jansen, Andreas
AU - Kircher, Tilo T. J.
AU - Knöchel, Christian
AU - Kramer, Bernd
AU - Lafer, Beny
AU - López-Jaramillo, Carlos
AU - Machado-Vieira, Rodrigo
AU - MacIntosh, Bradley J.
AU - Melloni, Elisa M. T.
AU - Mitchell, Philip B.
AU - Nenadic, Igor
AU - Nery, Fabiano
AU - Nugent, Allison C.
AU - Oertel, Viola
AU - Ophoff, Roel A.
AU - Ota, Miho
AU - Overs, Bronwyn J.
AU - Pham, Daniel L.
AU - Phillips, Mary L.
AU - Pineda-Zapata, Julian A.
AU - Poletti, Sara
AU - Polosan, Mircea
AU - Pomarol-Clotet, Edith
AU - Pouchon, Arnaud
AU - Quidé, Yann
AU - Rive, Maria M.
AU - Roberts, Gloria
AU - Ruhe, Henricus G.
AU - Salvador, Raymond
AU - Sarró, Salvador
AU - Satterthwaite, Theodore D.
AU - Schene, Aart H.
AU - Sim, Kang
AU - Soares, Jair C.
AU - Stäblein, Michael
AU - Stein, Dan J.
AU - Tamnes, Christian K.
AU - Thomaidis, Georgios V.
AU - Upegui, Cristian Vargas
AU - Veltman, Dick J.
AU - Wessa, Michèle
AU - Westlye, Lars T.
AU - Whalley, Heather C.
AU - Wolf, Daniel H.
AU - Wu, Mon-Ju
AU - Yatham, Lakshmi N.
AU - Zarate, Carlos A.
AU - Thompson, Paul M.
AU - Andreassen, Ole A.
AU - ENIGMA Bipolar Disorder Working Group
N1 - Funding Information:
O. A. A. received Speaker's honorarium from Lundbeck and is a consultant for HealthLytix. M. B. was supported by an unrestricted grant from AstraZeneca. A. C. B. is a full‐time employee of P1vital Ltd. C. R. K. C. and P. M. T. have received partial research support from Biogen, Inc. (Boston, USA) for work unrelated to the topic of this manuscript. T. E. has received a speaker's fee from Lundbeck. G. M. G. is a NIHR Emeritus Senior Investigator, holds shares in P1vital and P1Vital products and has served as consultant, advisor or C. M. E. speaker in the last 3 years for Allergan, Angelini, Compass pathways, MSD, Janssen, Lundbeck (/Otsuka or /Takeda), Medscape, Minerva, P1Vital, Pfizer, Sage, Servier, Shire, Sun Pharma. D. P. H. is a full‐time employee of Genentech, Inc. A. M. M. has received research support from the Eli Lilly, Janssen and The Sackler Trust. J. C. S. has participated in research funded by Forest, Merck, BMS, and GSK and has been a speaker for Pfizer and Abbott. Marsal Sanches has received research grants from Janssen. All other authors from this site report no conflicts of interest to declare. D. J. S. has received research grants and/or consultancy honoraria from Lundbeck and Sun. E. V. has received grants and served as consultant, advisor or CME speaker for the following entities (work unrelated to the topic of this manuscript): AB‐Biotics, Abbott, Allergan, Angelini, Dainippon Sumitomo Pharma, Galenica, Janssen, Lundbeck, Novartis, Otsuka, Sage, Sanofi‐Aventis, and Takeda.
Funding Information:
The São Paulo (Brazil) studies have been supported by grants from FAPESP‐Brazil (#2009/14891‐9, 2010/18672‐7, 2012/23796‐2 & 2013/03905‐4), CNPq‐Brazil (#478466/2009 & 480370/2009), the Wellcome Trust (UK) and the Brain & Behavior Research Foundation (2010 NARSAD Independent Investigator Award granted to Geraldo F. Busatto). C. A. Z. was supported by Intramural Research Program, National Institute of Mental Health. L.‐L. Z. was supported by National Natural Science Foundation of China (61722313), Fok Ying Tung Education Foundation (161057), and Science & Technology Innovation Program of Hunan Province (2018RS3080). Lastly, we would like to thank all of the ENIGMA Consortium Working Group Members for all their efforts in helping this international consortium effort thrive.
Publisher Copyright:
© 2020 The Authors. Human Brain Mapping published by Wiley Periodicals LLC.
PY - 2022/1
Y1 - 2022/1
N2 - MRI-derived brain measures offer a link between genes, the environment and behavior and have been widely studied in bipolar disorder (BD). However, many neuroimaging studies of BD have been underpowered, leading to varied results and uncertainty regarding effects. The Enhancing Neuro Imaging Genetics through Meta-Analysis (ENIGMA) Bipolar Disorder Working Group was formed in 2012 to empower discoveries, generate consensus findings and inform future hypothesis-driven studies of BD. Through this effort, over 150 researchers from 20 countries and 55 institutions pool data and resources to produce the largest neuroimaging studies of BD ever conducted. The ENIGMA Bipolar Disorder Working Group applies standardized processing and analysis techniques to empower large-scale meta- and mega-analyses of multimodal brain MRI and improve the replicability of studies relating brain variation to clinical and genetic data. Initial BD Working Group studies reveal widespread patterns of lower cortical thickness, subcortical volume and disrupted white matter integrity associated with BD. Findings also include mapping brain alterations of common medications like lithium, symptom patterns and clinical risk profiles and have provided further insights into the pathophysiological mechanisms of BD. Here we discuss key findings from the BD working group, its ongoing projects and future directions for large-scale, collaborative studies of mental illness.
AB - MRI-derived brain measures offer a link between genes, the environment and behavior and have been widely studied in bipolar disorder (BD). However, many neuroimaging studies of BD have been underpowered, leading to varied results and uncertainty regarding effects. The Enhancing Neuro Imaging Genetics through Meta-Analysis (ENIGMA) Bipolar Disorder Working Group was formed in 2012 to empower discoveries, generate consensus findings and inform future hypothesis-driven studies of BD. Through this effort, over 150 researchers from 20 countries and 55 institutions pool data and resources to produce the largest neuroimaging studies of BD ever conducted. The ENIGMA Bipolar Disorder Working Group applies standardized processing and analysis techniques to empower large-scale meta- and mega-analyses of multimodal brain MRI and improve the replicability of studies relating brain variation to clinical and genetic data. Initial BD Working Group studies reveal widespread patterns of lower cortical thickness, subcortical volume and disrupted white matter integrity associated with BD. Findings also include mapping brain alterations of common medications like lithium, symptom patterns and clinical risk profiles and have provided further insights into the pathophysiological mechanisms of BD. Here we discuss key findings from the BD working group, its ongoing projects and future directions for large-scale, collaborative studies of mental illness.
KW - ENIGMA
KW - MRI
KW - bipolar disorder
KW - cortical surface area
KW - cortical thickness
KW - mega-analysis
KW - meta-analysis
KW - neuroimaging
KW - psychiatry
KW - volume
UR - https://www.scopus.com/pages/publications/85088655322
U2 - 10.1002/hbm.25098
DO - 10.1002/hbm.25098
M3 - Review article
C2 - 32725849
SN - 1065-9471
VL - 43
SP - 56
EP - 82
JO - Human brain mapping
JF - Human brain mapping
IS - 1
ER -
SDG 3 Good Health and Well-being